Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer
Sign Up to like & getrecommendations! Published in 2022 at "Science Translational Medicine"
DOI: 10.1126/scitranslmed.abo5959
Abstract: ESR1 (estrogen receptor 1) hotspot mutations are major contributors to therapeutic resistance in estrogen receptor–positive (ER+) breast cancer. Such mutations confer estrogen independence to ERα, providing a selective advantage in the presence of estrogen-depleting aromatase… read more here.
Keywords: estrogen receptor; esr1; breast cancer; giredestrant ... See more keywords
Evaluation of pharmacodynamic (PD) and biologic activity in a preoperative window-of-opportunity (WOO) study of giredestrant (GDC-9545) in postmenopausal patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2–) operable breast cancer (BC).
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.577
Abstract: 577 Background: Modulation of ER activity and/or estrogen synthesis is the mainstay therapeutic strategy in ER+ BC treatment. Giredestrant is a highly potent, nonsteroidal oral selective ER degrader (SERD) that achieves robust ER occupancy and… read more here.
Keywords: her2 operable; treatment; activity; tumor ... See more keywords
Volumetric absorptive microsampling-LC-MS/MS assays for quantitation of giredestrant in dried human whole blood.
Sign Up to like & getrecommendations! Published in 2023 at "Bioanalysis"
DOI: 10.4155/bio-2022-0189
Abstract: Volumetric absorption microsampling devices offer minimally invasive and user-friendly collection of capillary blood in volumes as low as 10 μl. Herein we describe the assay validation for determination of the selective estrogen receptor degrader giredestrant (GDC-9545)… read more here.
Keywords: dried human; human whole; quantitation giredestrant; giredestrant ... See more keywords